Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 1 clinical study titled A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etentamig (ABBV-383) Monotherapy in Japanese Subjects With Relapsed or Refractory Multiple Myeloma (4L+ RRMM Monotherapy Study). The study aims to assess adverse events and changes in disease state in adult participants with relapsed or refractory multiple myeloma (R/R MM) in Japan, highlighting its significance in addressing this incurable disease.
The intervention being tested is Etentamig (ABBV-383), an investigational drug administered intravenously. The study explores two increasing doses to determine a tolerable dose for treating R/R MM.
This interventional study follows a non-randomized, sequential intervention model without masking. Its primary purpose is treatment, focusing on evaluating the safety and efficacy of Etentamig.
The study began on March 24, 2022, with an active but not recruiting status as of the last update on August 7, 2025. These dates are crucial for tracking the study’s progress and timeline.
The update on this study could influence AbbVie’s stock performance and investor sentiment, as successful results may enhance the company’s position in the competitive multiple myeloma treatment market. Investors should monitor this development, considering the broader industry context.
The study is ongoing, with further details available on the ClinicalTrials portal.